Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN01 Vaccine for Post-COVID Fibrosing ILD
NCT04537130Phase 1Unknown
- Sponsor
- Instituto Oncológico Dr. Rosell
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Implantable Devices, Transdermal Patches, Genetically Modified Bacteria
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IN01 in pulmonary fibrosis (PF) (2 arms), sponsored by Instituto Oncológico Dr. Rosell. Primary endpoint: Frequency and severity of Adverse Events at 1 year. Status: unknown.
02
Drugs
IN01
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04537130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537130.